chief business officer and head of corporate development...Protea Biosciences Inc., of Morgantown, W. Va., added Thijs Spoor and Josiah T. Austin to its board

Moderna Therapeutics Inc., of Cambridge, Mass., named Stephen Hoge, senior vice president of corporate development and new drug concepts...OvaScience Inc., of Cambridge, Mass., named Alison Lawton chief operating officer and Christopher Beck chief commercial officer...Relypsa Inc., of Redwood City, Calif., added Paul J. Hastings and David W.J. McGirr to its board

Cell Therapeutics Inc., of Seattle, appointed Matthew J. Plunkett executive vice president, corporate development...Eli Lilly and Co., of Indianapolis, named Michael Harrington senior vice president and general counsel

Conatus Pharmaceuticals Inc., of San Diego, appointed Mark Morris head of biostatistics and Daniel Ripley head of corporate development...Quanterix Corp., of Lexington, Mass., named Paul Chapman president and CEO

Gilead Sciences Inc., of Foster City, Calif., appointed Paul Boateng and Hannah Kettler to its health policy advisory board...Macrocure, of Petach Tikva, Israel, named Nissim Mashiach president and CEO...ViaCyte Inc., of San Diego, appointed Paul Laikind president and CEO

named CFO Timothy Morris senior vice president, global corporate development and finance

PTC Therapeutics Inc., of South Plainfield, N.J., named Claudia Hirawat president and Mark Boulding executive vice president and chief legal officer...Synta Pharmaceuticals Corp., of Lexington, Mass., appointed George Farmer vice president of corporate development

and Christine Mikail, executive vice president, corporate development, general counsel and secretary

and added Eunan Maguire senior vice president of strategy and corporate development

and added Eunan Maguire senior vice president of strategy and corporate development

MethylGene Inc., of Montreal, appointed Joseph Walewicz vice president of business and corporate development...NuPathe Inc., of Conshohocken, Pa., appointed Bart J. Dunn vice president of corporate development and licensing

Rib-X Pharmaceuticals Inc., of New Haven, Conn., promoted Erin Duffy to chief scientific officer and Jarrod Longcor to vice president of corporate development...Silence Therapeutics plc, of London, appointed Thomas Christely CEO and named Tony Sedgwick chief business officer

Ablexis LLC, of San Francisco, appointed Jake Bauer senior director of corporate development and business operations

It also named Ben Machielse and Robert Gailus to its board...TetraLogic Pharmaceuticals Inc., of Malvern, Pa., appointed Jonathan B. Lloyd Jones chief financial officer and vice president of corporate development

Patheon, of Toronto, appointed Michael E. Lytton executive vice president of corporate development and strategy and general counsel...PolyTherics Ltd., of London, named John Burt CEO and board member after Keith Powell stepped down

Numerate Inc., of San Bruno, Calif., appointed David Jobes senior vice president of business and corporate development...Seattle Genetics Inc., of Bothell, Wash., appointed Natasha Hernday vice president of corporate development and promoted Eric Sievers vice president of clinical affairs

The firm also nominated Stuart Strathdee and Ganesh Kishore to its board...Gilead Sciences Inc., of Foster City, Calif., appointed Muzammil M. (Muz) Mansuri senior vice president of R&D strategy and corporate development

Infinity Pharmaceuticals Inc., of Cambridge, Mass., appointed Joshua D. Hamermesh vice president of business and corporate development...Lightlake Therapeutics Inc., of London, appointed Cynthia McCormick as senior clinical and regulatory advisor

Stellar Biotechnologies Inc., of Port Hueneme, Calif., appointed Michael R. McClurg vice president of business development and marketing and changed Darrell Brookstein's title to executive vice president of corporate development and finance